Fundraising FoxFoster City · Series B–Late Stage · 19 people tracked
Also known as Gilead
Find your way into Gilead Sciences
Sign up to see every warm intro you have to Gilead Sciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Gilead Sciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Gilead's research and development approach centers on pursuing transformative medicines and cures across three therapeutic areas: virology, oncology and inflammation. Drawing on a 35-plus-year track record, the company identifies best-in-class molecules, biologics, cell therapies and combinations and advances them quickly. It has helped turn public health challenges such as HIV and hepatitis C into manageable or curable conditions, and is developing therapies across viral hepatitis, SARS-CoV-2 and potential pandemic viruses. In oncology it seeks treatments offering long-term remission and cures, while in immunology it targets next-generation therapies for inflammatory and fibrotic diseases. The company set an ambition in 2019 to deliver 10-plus transformative therapies by 2030.
Source: firm website, verified Aug 16, 2026.
Team · 19 people
from the firm's website & public directories
Serves as Gilead's Chief Medical Officer (MD, PhD).
Serves as EVP of Research (MD).
Johanna Mercier serves as Chief Commercial and Corporate Affairs Officer at Gilead Sciences.
What they invest in
from 10 of 10 portfolio companiesBiotech ×10Healthtech ×5Medical Devices ×3AI & Machine Learning ×2Deep Tech ×2Digital Health ×1SaaS ×1
HQs:United States×7United Kingdom×1
Investments · 10 tracked
founders shown can be your intro pathBy year:2023 · 12022 · 12021 · 22020 · 12018 · 27 dated
Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Arie Belldegrun, M.D.(Executive Chairman and Co-Founder)inDavid Chang, M.D., Ph.D.(Co-Founder, Allogene)Christine Cassiano(Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer and one of the founders)inZachary Roberts, M.D., Ph.D.(President and Chief Executive Officer)ROBERT ABRAHAM(Director)JOSHUA A. KAZAM(Co-Founder and Director of Allogene)
Co-investorsAvoro Capital AdvisorsForesite CapitalTPGVida Ventures
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific immunotherapies designed to guide T cells to treat autoimmune and inflammatory diseases.
BiotechDeep TechHealthtechMedical Devices
Geoffrey Lynn(Chief Scientific Officer)William Enright(Chief Executive Officer & Board Director)Leon Hooftman(Chief Medical Officer)Bill EnrightinAdrian Hill(Founder)Sarah Gilbert(Founder)
Co-investorsFuture Planet CapitalGV (Google Ventures)Oxford Science EnterprisesKorea Investment PartnersMilltrust International GroupTencent Holdings+1 more
Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset.
BiotechEmeryville, US
Warner Biddle(Chief Executive Officer)inBrian Kotzin(Director)Ian Clark(Director)Ryan Jones(Executive Officer)Karen Walker(Executive Officer)Peter Maag(Executive Officer, Director)in
Co-investorsBain Capital Life SciencesVida VenturesWestlake Village BioPartnersInsight PartnersKleiner PerkinsNorthpond Ventures+3 more
Tizona Therapeutics is a biotechnology company developing first-in-class immuno-oncology therapeutics, including its lead clinical-stage asset TTX-080, aimed at changing cancer progression and relapse.
AI & Machine LearningBiotechHealthtech
Vijay K. Kuchroo(Scientific Co-Founder & Advisory Board Member)Drew Pardoll(Scientific Co-Founder & Advisory Board Member)Dario Vignali(Scientific Co-Founder & Advisory Board Member)Jedd Wolchok(Scientific Co-Founder & Advisory Board Member)Christine O'Brien(Chief Executive Officer & Board Member)inCourtney Beers(Chief Scientific Officer)
Co-investorsCanaan PartnersMPM BioImpactAbingworthAstellas Venture Management LLCLightstone Ventures
Curebase provides a software platform for clinical trial management, serving contract research coordinators and trial sites.
AI & Machine LearningBiotechDigital HealthHealthtechSaaSFort Lauderdale, US
Storm Stillman(COO)inTom Lemberg(Founder)inMatthew Rials(CTO)Noah Debrincat(Lead Product Manager)inHannah Gittleman(Head of People)Sam Oliver(Lead Recruiter)
Co-investorsAcrew CapitalBold Capital PartnersBreyer CapitalC3 VenturesFuture Planet CapitalGaingels+15 more
__Twitter.png)
Cambridge, MA biotechnology company developing injectable synthetic biomarkers for noninvasive disease staging and treatment monitoring.
BiotechCambridge, US
Gabriel Kwong(Executive Officer)inSangeeta BhatiainRoopom Banerjee(Executive Officer)in
BoardTheresia Gouw(Director)inAmy Schulman(Director)Stan Lapidus(Director)in
Co-investorsGreatPoint VenturesAcrew CapitalARCH Venture PartnersAspect VenturesCatalio Capital ManagementCRV (Charles River Ventures)+7 more
Tentarix Biotherapeutics develops multifunctional biologics to modernize healthcare standards through precision medicine.
BiotechDeep TechHealthtechMedical Devices
BoardSrini Akkaraju(Director, Founder)inPaul Kang(Director, Founder)
Co-investorsVersant VenturesSamsara BioCapital
Tmunity Therapeutics was a University of Pennsylvania spinout developing engineered T-cell therapies, including CAR-T and TCR-based treatments, for cancers.
BiotechPhiladelphia, US
Anne Chew(Director and President)
BoardKevin Mahoney(Director)
Co-investorsAndreessen HorowitzKhosla VenturesKleiner PerkinsLAVLilly Asia VenturesMilitia Hill Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Exits · 5
3 IPOs · 2 acquisitions · showing 3Allogene TherapeuticsNASDAQ: ALLOBarinthusbioNASDAQ: BRNSKyverna TherapeuticsNASDAQ: KYTX
Portfolio news
latest coverage across their companies
Kyverna Therapeutics · biospace.com · Sep 3, 2026
Curebase · curebase.ai · May 6, 2025
IPO stake values · per SEC filings · 2
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Allogene Therapeutics | 6.5% | $18.00 | Oct 2018 | $134.8M |
| Kyverna Therapeutics | 7.9% | $22.00 | Feb 2024 | $70.8M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Gilead Sciences made?
- Gilead Sciences has 10 tracked investments, 5 of which have exited.
- What stage does Gilead Sciences invest at?
- Gilead Sciences invests at the Series B, Series C, Late Stage stages.
- What sectors does Gilead Sciences focus on?
- Gilead Sciences focuses on Advanced Manufacturing, Biotech, Healthtech, SaaS.
- Where is Gilead Sciences located?
- Gilead Sciences is headquartered in Foster City, US.
Media · Podcasts & interviews
featuring the teamGilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history
CNBC Television · Daniel O’Day
Hear more from CEO Daniel O’Day about Gilead Sciences' investment in U.S. innovation.
PhRMA · Daniel O’Day
Watch CNBC's full interview with Gilead Sciences chairman and CEO Daniel O’Day
Daniel O’Day · cnbc.com
Images
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
West Virginia Jobs Investment Trust is a publicly-funded venture capital provider that invests in eligible West Virginia businesses to support job creation and economic development within the state.
CIBC is a Canadian retail and commercial bank offering personal banking, investing (CIBC Investor's Edge), and financial advisory services to consumers.
Alumni Ventures (AV) is a venture capital firm that co-invests alongside lead VCs in startups, backing founders with capital and access to a large investor and operator community.
Chuangdongfang (创东方) is a Shenzhen-based investment firm focused on equity investment in technology and innovation-driven enterprises, engaging in venture, M&A, and industrial investment.